通过选择性PARP1降解剂最大限度地减少DNA捕获,同时保持通过选择性PARP1降解剂抑制活性
Li Chen1, Yahui Zou1, Renhong Sun2
1School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Cell death & disease
|December 18, 2024
概括
一个新的PROTAC分子,180055有效降解癌细胞中的多 (ADP-ribose) 聚合酶1 (PARP1). 这种有针对性的方法为传统的PARP1抑制剂提供了更安全的替代方案,对BRCA突变瘤有希望.
科学领域:
- 生物化学和分子生物学
- 癌症治疗方法 癌症治疗方法
- 药物发现 药物发现 药物发现
背景情况:
- 聚 (ADP-ribose) 聚合酶1 (PARP1) 对于DNA修复至关重要,也是癌症治疗的目标.
- 现有的PARP1抑制剂面临着由于DNA捕获和非目标效应的挑战.
- 需要改进的PARP1向疗法,具有更好的安全性.
研究的目的:
- 使用蛋白质降解技术开发针对PARP1的新型治疗策略.
- 为了合成和评估一种用于PARP1降解的蛋白质溶解向合体 (PROTAC) 分子.
- 在临床前癌症模型中评估PROTAC分子的疗效和安全性.
主要方法:
- 一个PROTAC分子 (180055) 的合成,将基于Rucaparib的部分与VHL连接体结合在一起.
- 在体外评估PARP1降解和酶抑制.
- 评估DNA陷效应和非目标活动.
- 在BRCA突变模型中的瘤细胞杀死以及对正常细胞的影响的体外和体内研究.
主要成果:
- 在PROTAC分子180055高效和选择性降解PARP1.
- 在没有显著的DNA捕获的情况下,PARP1酶活性被抑制.
- 180055证明了选择性杀死BRCA突变瘤细胞.
- 在体外和体内都观察到对正常细胞生长的影响最小.
结论:
- 合成的PROTAC分子180055有效地降解PARP1,具有高效率和安全性.
- 180055代表了一种有前途的新疗法候选人,用于同类重组缺陷的癌症,如BRCA突变瘤.
- 需要对180055进行进一步的临床研究.
相关概念视频
Restarting Stalled Replication Forks
5.7K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.7K
DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K


